COVID-19 vaccine effectiveness
(Randomized evidence)

Methods

Protocol

Analyses are updated every two weeks

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

go to metacovid

Vaccine types

Vaccine efficacy and safety for vaccine vs placebo / no vaccine (forest plots)

Vaccine efficacy and safety for vaccine vs vaccine (forest plots)

Vaccine efficacy and safety against variants of concern (forest plots)

Vaccine efficacy, immunogenicity and safety of heterologous vs homologous vaccination (tables)

Vaccine efficacy, immunogenicity and safety of booster vs no booster (tables)

Vaccine efficacy, immunogenicity and safety of booster VS booster (tables)

Trials reports under extraction

In addition to the below included trials, we have included and presently extracting 16 new vaccine randomized trials

Description of primary studies

In this table, we report the main characteristics of the COVID-19 vaccine candidates from RCTs identified, in addition to the overall risk of bias assessment.

As of January 2022, we will extract and present results of early phase trials only when the dose has been selected. Results from phase 1-2 studies are included in forest plots for the chosen vaccine dose and schedule only.

Search studies

Search by Vaccine name Author Registration number
Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04922788
Nanogen Pharmaceutical Biotechnology JSC.
Nguyen TP, medRxiv, 2022
New

Full text
Commentary
Commentary
Protein subunit

Nanocovax

Placebo

RCT
Phase 3
Healthy adult without previous or current SARS-CoV-2 infection in four centres in Vietnam. N=13007
Some concerns
Details

Full description

TCTR20210722003
AstraZeneca+University of Oxford
Nanthapisal S, Vaccine, 2022
Updated

Full text
Commentary
Commentary
Non replicating viral vector

CoronaVac/Boost ChAdOx1

CoronaVac Boosted by low dose ChAdOx1

RCT
Phase 2
Healthy adult volunteers with no history or current infection with SARS-CoV-2 who had completed two doses of CoronaVac at 2 centres in Thailand. N=422
Some concerns
Details

Full description

NCT04540419
CanSino Biological Inc./Beijing Institute of Biotechnology
Lioznov D, medRxiv, 2022
Prometheus

Full text
Commentary
Commentary
Non replicating viral vector

Ad5-nCoV 5x10^10vp D0

Placebo

RCT
phase 3
Healthy adult volunteers without obesity with no current or previous SARS-CoV-2 infection in 6 centres in Russia. N=500
Some concerns
Details

Full description

NCT04951388
Medigen Vaccine Biologics+Dynavax+NIAID
Liu LTC, medRxiv, 2022

Full text
Commentary
Commentary
Protein subunit

MVC-COV1901 15 mcg D0/28

Placebo

RCT
Phase 2
Adolescents aged 12 to 17 years with no serious medical conditions and no previous SARS-CoV-1 infection or vaccination at 5 centers in Taiwan. N=399
Some concerns
Details

Full description

NCT04962906; NCT05027672
Gamaleya Research Institute, AstraZeneca+University of Oxford;Moderna;Sinopharm
Macchia A, Lancet Reg Health Am, 2022

Full text
Commentary
Non replicating viral vector

Gam-COVID-Vac rAd26-S

Gam-COVID-Vac rAd26-S/BBIBP-CorV

RCT
Phase 2
Adults who had received the first dose (rAd26) of the Sputnik V vaccine at least 30 days earlier and no history of SARS-CoV-2 at a single centre in Argentina N=540
Some concerns
Details

Full description

NCT05142319
Pfizer/BioNTech+Fosun Pharma; ModernaTX
Poh XY, SSRN, 2022

Full text
Commentary
Commentary
RNA based vaccine

Boost mRNA-1273 after prime vaccination with BNT162b2

Boost BNT162b2 after prime vaccination with BNT162b2

RCT
3
Adults at a single center in Singapore with no previous history of COVID-19 who had received a primary series of BTN162b2 at least 6 months previously N=100
Some concerns
Details

Full description

NCT04955626
Pfizer/BioNTech+Fosun Pharma
Moreira E D, N Engl J Med, 2022

Full text
Commentary
RNA based vaccine

Boost BNT162b2 after prime vaccination with BNT162b2

BNT162b2

RCT
Phase 3
Adults and adolescents (from age of 16 years) that had received two doses BNT162b2 in a previous trial at least 6 months previously and had no history of COVID-19 at 123 sites in Brazil, South Africa, and the USA N=10136
Some concerns
Details

Full description

RPCEC00000346
Center for Genetic Engineering and Biotechnology (CIGB)
Hernandez-Bernal, medRxiv, 2021 (a)
ABDALA

Full text
Commentary
Commentary
Protein subunit

25mcg CIGB D0/D14/D28

25mcg CIGB D0/D28/D56

50mcg CIGB D0/D28/D56

50mcg CIGB D0/D14/D28

Placebo

RCT
Phase 1
Healthy adults that were SARS-CoV-2 infection-free and with no recent contact or high-risk of exposure to COVID-19 at a single center in Cuba N=132
Some concerns
Details

Full description

RPCEC00000346
Center for Genetic Engineering and Biotechnology (CIGB)
Hernandez-Bernal , medRxiv, 2021 (b)
ABDALA

Full text
Commentary
Commentary
Protein subunit

25mcg CIGB D0/D14/D28

50mcg CIGB D0/D14/D28

Placebo

RCT
Phase 2
Healthy adults 19 to 80 years old that were SARS-CoV-2 infection-free and with no recent contact or high-risk of exposure to COVID-19 at a single center in Cuba N=726
Some concerns
Details

Full description

NCT04677660
ModernaTX
Masuda T, Vaccine, 2022

Full text
Commentary
RNA based vaccine

mRNA-1273

Placebo

RCT
Phase 1-2
Healthy adults aged ≥ 20 years with no known history/risk of SARS-CoV-2 infection at 2 centers in Japan. N=200
Some concerns
Details

Full description